Fri, Jun 20, 1:47 PM (29 days ago)
Vitro BioPharma, Inc. (VBP) reported its financial results for the quarter ending April 30, 2025. The company experienced a net loss of $1.5 million, a decrease from the $3.1 million loss in the same quarter of 2024. Revenue for the quarter was $511,584, down 11% from $572,937 in the previous year. Gross profit margins decreased to 74% from 84% due to higher production costs. Operating expenses, including selling, general, and administrative costs, and research and development expenses, were $1.46 million and $222,431, respectively. Interest expense saw a significant reduction to $395,960 from $2.16 million, primarily due to debt discount accretion reductions. The company's cash position declined to $198,075 from $571,360, with a working capital deficit of $13.3 million. VBP continues to face substantial doubt about its ability to continue as a going concern, relying on additional capital through equity or debt financings. The company is pursuing clinical trials for its AlloRx Stem Cell therapy and expects to increase revenue through its subsidiaries, InfiniVive MD and Fitore. Despite these efforts, VBP's financial health remains precarious, with ongoing losses and a need for significant additional funding.